More information to come.

Dr. Elisia Clark, Senior Scientist at MJFF, is part of the Preclinical Research Tools Program, driving efforts to develop and validate high-quality research tools to advance Parkinson's research. Through partnerships, this program has resulted in 50+ novel antibodies to date.

Dr Carly Dix is Associate Director at AstraZeneca UK, leading the Affinity Reagents Team within Biologics Engineering. Since joining AZ in 2015 Carly has worked on the selection, generation and validation of antibodies and has an interest in antibody validation best practice.

Myriam Duckely, Ph.D., is a Senior Principal Scientist at Novartis, specializing in drug discovery targeting human GPCRs and transporters. She is currently Program Director of FreeNovation, a philanthropic program.

Dr Will Howat is the VP of Validation and Technical Quality at Abcam. Abcam has a keen interest in antibody validation and ensuring quality is a key driver for future scientific publications.

Elena Ivanova is the head of the pre-clinical histology core, specialized on IHC and IF Multiplex assays, serving all therapeutic areas at Regeneron.

More information to come.

Ulf Landegren, Uppsala professor, develops molecular tools for nucleic acid and protein analysis. He's a member of EMBO and the Royal Swedish Academy, with 230+ publications and 55+ patents. His lab gave rise to companies like Olink and Navinci, and his tech is licensed by major biotech firms.

Deborah, with a Ph.D. from MIT, has extensive biotech/pharma experience at Pfizer, Novartis, and SUGEN. She's an entrepreneur, having led Cell Assay Innovations for a decade. Currently, she directs antibody validation at IPI, focusing on quality control and testing.

More information to come.

More information to come.

Roberto has been Cell Signaling Technology's CSO since 2005. Before helping start CST in 1999, he was a scientist at New England Biolabs. He holds a PhD in molecular biology and completed a postdoctoral fellowship at the Whitehead Institute at MIT.

Dr. Andrea Radtke, is passionate about open science, she co-leads community antibody validation initiatives. Since August 2024, she has been a Principal Scientist at Leica Microsystems.

Dr. Trimmer, a UC Davis neuroscientist, develops antibodies for neuroscience research. With 200+ publications, he directs the NeuroMab Facility, working on highly characterized monoclonal and recombinant antibody production, hybridoma sequencing and more.

Dr. Michael P. Weiner developed key technologies, including QuikChange mutagenesis, next-gen DNA sequencing and emulsion PCR, and DNA barcoding Luminex beads. A serial entrepreneur, he has founded multiple biotech firms and holds over 50 patents.

Libby is an AstraZeneca Senior Scientist in the Translational Pathology group within Early Oncology Cancer Biomarker Development. She focuses on antibody validation, especially PTMs, and studies pre-analytical factors affecting labile biomarkers.

Dr. Harvinder Virk, NIHR lecturer in Respiratory Sciences, has a focus on better research translation. He co-leads the Only Good Antibodies and UK YCharOS teams and their projects. He's a Royal College of Physicians member and on the UK Reproducibility Network Supervisory board.

More information to come.

More information to come.